MedTrace Logo

Analysis of Circulating Tumor mArkers in Blood 4 - ALCINA 4

NCT05088395 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2050

Last updated 2026-04-14

No results posted yet for this study

Summary

Multi-cohort exploratory prospective study. Participation in the ALCINA 4 study does not change the standard management of the patient, including the treatments administered. A sampling schedule will be set up for each cohort.

Depending on the clinical context studied and the biomarkers studied and/or sought, the timing of blood samples will vary between cohorts. There may be up to 4 samples (or more) taken per patient for up to 18, 24 or 36 months. If a specific tumor sample is required, it will be collected only once during the study.

Conditions

Interventions

OTHER

Blood sample

Depending on the clinical context studied and the biomarkers studied and/or sought, the timing of blood samples will vary between cohorts. There may be up to 4 samples (or more) taken per patient for up to 18, 24 or 36 months according to the cohorts.

OTHER

Biopsy

If a specific tumor sample is required, it will be collected only once during the study

Sponsors & Collaborators

  • Institut Curie

    lead OTHER

Principal Investigators

  • Francois-Clement BIDARD · Institut Curie

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-19
Primary Completion
2031-06-01
Completion
2031-06-01

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05088395 on ClinicalTrials.gov